Amrize (NYSE:AMRZ) Price Target Lowered to $55.00 at Oppenheimer

Key Points

• Oppenheimer lowered Amrize’s price target to $55 from $62 while maintaining an “outperform” rating, implying approximately 43.9% upside from the previous close.
• Analyst sentiment is mixed: Amrize has a consensus rating of “Hold” and an average price target of $54.88, with recent downgrades from RBC, Citigroup and Truist.
• Amrize reported quarterly EPS of $0.88, below the $0.92 consensus estimate, on revenue of $3.49 billion. Company insiders have nevertheless purchased nearly 49,000 shares worth about $2.16 million over the past 90 days.

Amrize (NYSE:AMRZ - Get Free Report) had its target price reduced by stock analysts at Oppenheimer from $62.00 to $55.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has an "outperform" rating on the stock. Oppenheimer's price objective suggests a potential upside of 43.93% from the company's previous close.

AMRZ has been the topic of a number of other research reports. Morgan Stanley set a $63.00 target price on Amrize and gave the company an "overweight" rating in a research report on Monday, June 22nd. Sanford C. Bernstein reissued an "outperform" rating on shares of Amrize in a research report on Monday, June 22nd. Royal Bank Of Canada cut shares of Amrize from a "sector perform" rating to an "underperform" rating and decreased their price objective for the company from $60.00 to $48.00 in a research note on Monday, August 10th. Citigroup downgraded shares of Amrize from a "buy" rating to a "cautious" rating in a report on Wednesday, September 9th. Finally, Truist Financial reissued a "hold" rating and set a $48.00 target price (down from $65.00) on shares of Amrize in a report on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, eight have issued a Hold rating and four have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $54.88.

Amrize Price Performance

AMRZ stock opened at $38.21 on Friday. The company has a current ratio of 1.10, a quick ratio of 0.73 and a debt-to-equity ratio of 0.33. The company has a 50-day moving average price of $46.24 and a 200 day moving average price of $51.73. Amrize has a 12 month low of $38.17 and a 12 month high of $65.94. The stock has a market cap of $21.13 billion, a PE ratio of 17.61, a P/E/G ratio of 1.14 and a beta of 0.04.

Amrize (NYSE:AMRZ - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $0.88 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.04). The business had revenue of $3.49 billion for the quarter. Amrize had a net margin of 9.89% and a return on equity of 10.22%. Equities research analysts anticipate that Amrize will post 2.67 earnings per share for the current year.

Insider Activity at Amrize

In other news, CFO Baris Oran acquired 3,000 shares of the company's stock in a transaction dated Tuesday, August 11th. The shares were acquired at an average price of $47.38 per share, with a total value of $142,140.00. Following the purchase, the chief financial officer directly owned 3,000 shares of the company's stock, valued at $142,140. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jacques Sanche bought 4,150 shares of the business's stock in a transaction dated Wednesday, August 26th. The shares were purchased at an average cost of $45.02 per share, with a total value of $186,833.00. Following the completion of the acquisition, the director owned 9,766 shares in the company, valued at approximately $439,665.32. This represents a 73.90% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought 48,983 shares of company stock valued at $2,158,755 in the last 90 days. 0.54% of the stock is currently owned by corporate insiders.

Institutional Trading of Amrize

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AMRZ. MCF Advisors LLC purchased a new stake in shares of Amrize during the 4th quarter worth about $27,000. Basepoint Wealth LLC purchased a new position in Amrize during the fourth quarter worth approximately $33,000. Continuum Advisory LLC acquired a new stake in Amrize in the second quarter valued at approximately $62,000. NewEdge Advisors LLC grew its holdings in Amrize by 1,419.7% in the second quarter. NewEdge Advisors LLC now owns 2,082 shares of the company's stock valued at $111,000 after purchasing an additional 1,945 shares during the period. Finally, Oslo Pensjonsforsikring AS purchased a new stake in shares of Amrize in the first quarter valued at approximately $133,000.

Amrize Company Profile

Amrize is a North American building materials and solutions company formed through the separation of Holcim's North American business. The company began trading publicly on the New York Stock Exchange in 2025 under the symbol AMRZ.

Amrize supplies essential construction materials, including cement, aggregates, ready-mix concrete and asphalt. It also provides a range of building products and solutions used in residential, commercial and infrastructure construction, including concrete products, roofing systems and other materials designed to support building and construction projects.

The company serves customers across the United States and Canada through a network of production facilities, distribution operations and local businesses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.